Philogen SpA raises €62m to push registr...Privately financed Italian antibody-cytokine fusion protein specialist Philogen SpA has secured €62m from private investors including the Neri and Dompé families to push registration of two … more ➔
Halt of Polyphor trial shrinks company val...Roche had a nose for success when the pharma giant ended the CHF500m deal with Polyphor in November 2015. Now, the antibiotics maker stopped a Phase III trial of its lead murepavadin (Pol7080). more ➔
Ethics Council calls for moratorium of cli...Following the birth of genome-edited twins in China, the German Ethics Council has provided a complete ethical review about human germline intervention. more ➔
BioNtech aquires antibody assets from MabV...Immunotherapy and infection specialist BioNTech SE (Mainz, Germany) has acquired preclinical and clinial antibody assets and infrastructior from MabVax Therapeutics Holding, Inc. more ➔
MS linked to epigenetic changes in immune...Epigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment. more ➔
Confo Therapeutics raise €30m in Series...The round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributi … more ➔
Researchers report how body fat affects im...US scientists have found that the complex interactions between fat tissue and the immune system are mediated by interleukin 33 (IL-33). more ➔
European Lead Factory gets €36.5m suppor... The European Lead Factory (ELF) – a drug discovery hub for validation new targets from academia and biotech SMEs – has again received project funding from the Innovative Medicine’s Initiative. more ➔
AstraZeneca set to licence 5 programmes fr...Transgène SA and AstraZeneca plc have entered into a collaboration and exclusive license option agreement on Transgène’s armed oncolytic immunotherapies. more ➔
Alentis Therapeutics debuts with CHF12.5m Liver specialist Alentis Therapeutics AG has raised CHF12.5m in a Series A round co-led by BioMedPartners and BB Pureos Bioventures. more ➔
